olverembatinib
Sponsor Ascentage Pharma Group International · listed as AAPG
olverembatinib is a drug asset sponsored by Ascentage Pharma Group International, listed as AAPG. CSA tracks 2 forward catalysts for it — the nearest is a readout expected Mar 31, 2027 (day precision, medium confidence), tied to trial NCT06640361. That trial is in Phase 3 and currently recruiting, studying GIST. It appears across 3 tracked trials in the CSA sample.
Next catalyst
Trial & sponsor
All tracked catalysts for olverembatinib
| Date | Event | Confidence | Trial |
|---|---|---|---|
| 2027-03-31 | READOUT | medium | NCT06640361 |
| 2027-12-31 | READOUT | medium | NCT06051409 |
Trials for olverembatinib in the CSA sample
| Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|
| NCT06640361 catalyst | Phase 3 | Recruiting | 2027-03-31 | Experimental | Ascentage Pharma Group Inc. | GIST |
| NCT06423911 | Phase 3 | Recruiting | 2027-06-30 | Other | Ascentage Pharma Group Inc. | Chronic Myeloid Leukemia; CML; CML, Chronic Phase |
| NCT06051409 catalyst | Phase 3 | Recruiting | 2027-12-31 | Experimental | Ascentage Pharma Group Inc. | Ph+ ALL; Leukemia, Lymphoblastic, Acute, Philadelphia-Positive |
Each trial links to its ClinicalTrials.gov record; primary completion dates are as registered there.
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 → More AAPG catalysts